Edition:
United States

Evolva Holding SA (EVE.S)

EVE.S on Swiss Exchange

0.57CHF
12:29pm EDT
Change (% chg)

CHF0.02 (+3.64%)
Prev Close
CHF0.55
Open
CHF0.55
Day's High
CHF0.57
Day's Low
CHF0.55
Volume
281,403
Avg. Vol
2,267,313
52-wk High
CHF0.94
52-wk Low
CHF0.37

EVE.S

Chart for EVE.S

About

Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company’s nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The... (more)

Overall

Beta: 2.74
Market Cap(Mil.): CHF219.56
Shares Outstanding(Mil.): 399.20
Dividend: --
Yield (%): --

Financials

  EVE.S Industry Sector
P/E (TTM): -- 48.09 29.63
EPS (TTM): -0.09 -- --
ROI: -17.51 -2.54 13.01
ROE: -19.94 5.17 14.16

BRIEF-Evolva Holding teams up with FCI to expand nootkatone and valencene in Europe

* Teams up with FCI to expand nootkatone and valencene sales & marketing in Europe Source text - http://bit.ly/2ncCLGP Further company coverage: (Gdynia Newsroom)

Mar 16 2017

BRIEF-Evolva secures equity financing of up to CHF 30 million

* Evolva secures equity financing of up to CHF 30 million and provides further preliminary financials for 2016

Mar 15 2017

BRIEF-Evolva Holding secures equity financing of up to CHF 30 million

* Secures equity financing of up to 30 million Swiss francs ($29.7 million) and provides further preliminary financials for 2016

Mar 15 2017

BRIEF-Evolva Holding: 2nd technical milestone under the multi-yr R&D alliance with Takasago

* Announces reaching the second technical milestone under the multi-year research and development alliance with Takasago

Mar 09 2017

Shares of sweetener maker Evolva sour after revenue warning

ZURICH, Jan 10 Food additive maker Evolva's shares tumbled more than a fifth in early trading on Tuesday after the Swiss company issued a profit warning and said its stevia-based sweetener Eversweet will not be launched until 2018.

Jan 10 2017

BRIEF-Evolva Holding sees FY 2016 revenues at CHF 9-10 million

* Evolva provides update on Stevia collaboration and 2016 preliminary top-line numbers

Jan 10 2017

BRIEF-Evolva Holding appoints Oliver Walker as CFO

* Announces appointment of Oliver Walker as its chief financial officer (CFO) effective 1st December 2016

Nov 29 2016

BRIEF-Ers Genomics and Evolva sign license agreement on CRISPR-Cas9 genome editing patents

* Ers Genomics and Evolva sign license agreement on CRISPR-Cas9 genome editing patents for industrial applications Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 27 2016

More From Around the Web

Earnings vs. Estimates